Related Experiment Videos

Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications

M A Caligiuri1

  • 1Department of Medicine, Rosewll Park Cancer Institute, Buffalo, NY 14263.

Seminars in Oncology
|December 1, 1993
PubMed
Summary

Interleukin-2 (IL-2) is vital for immune response. Further research into IL-2 receptors and clinical trials with recombinant IL-2 (rIL-2) may unlock new treatments for infections and cancers.

Related Concept Videos